

Health Cluster

“Theranostics in Nuclear Medicine”



© iStock

Realization	On-site Event
Location	DAAD Regional Office Cairo 11 El Saleh Ayoub St. Zamalek, Cairo, Egypt
Date	Thursday, 9 th November 2023 from 11 a.m. to 1.30 p.m. (Cairo Local Time)
Guests	Researchers and Scientists working in the medical and health field that are resident in Egypt
Duration	2,5 h
Coordinator and Contact Person	Nermine Abdelaty (abdelaty@daadcairo.org)
Organiser	DAAD Regional Office Cairo German Academic Exchange Service URL: www.daad.eg

Concept Note

Sometime in the early 2000s, the word “theranostics” (or “theragnostics”) started surfacing in the medical literature. Theranostics (from the Greek *therapeuein* “to treat medically” and *gnosis* “knowledge”) is the use of individual patient-level biological information in choosing the optimal therapy for that individual. In the modern era of “personalized medicine”, theranostics is increasingly pursued in many branches of medicine in order to develop ever more effective treatment regimens. Today the approach is successfully applied to the management of thyroid cancer, prostate cancer, neuroendocrine tumors and more to come. The concept of theranostics in nuclear medicine can even be expanded well beyond the specific transporter or receptor based diagnostics and therapies. In the broader sense, the use of F-18-fluorodeoxyglucose (FDG) PET/CT in oncology is a form of theranostics, especially when linked to a decision on therapy.

The event is organised within the framework of the DAAD Regional Office Cairo project “Clusters of Scientific Innovation in the Middle East and North Africa” (COSIMENA), which aims to strengthen and initiate scientific cooperation and to make networks of researchers and universities between Germany and the MENA region visible. As a result, existing cooperation is made visible and potential synergies are initiated.

Biography of the Speaker



After qualifying from medical school (1985-1992) from the University of Essen, ML undertook training in paediatric haematology/oncology at the University of Madison, Wisconsin, USA. From there, ML went on to take a 6-year fellowship in the Department of Nuclear Medicine at the University of Würzburg, where, in November 2000, he became a consultant. In 2008 ML moved to the University of Ulm to become professor of nuclear medicine and in June 2013 became full professor and chairman of the Department of Nuclear Medicine at the University of Marburg.

ML has among others been involved in multiple clinical trials in neurology, endocrinology (i.e. endocrine oncology) and paediatric oncology, including several multicentric, international trials in differentiated thyroid carcinoma. In addition, he is a member of numerous medical societies, including the German Society of Nuclear Medicine, the European Organization for Research and Treatment of Cancer (EORTC) Endocrine Tumor Study Group, and the European Association of Nuclear Medicine (EANM). From 2008 to 2012 he was chairman of the therapy committee for the European Association of Nuclear Medicine. From 2014 to 2020 he was chairing the Thyroid Committee of the EANM. He is a member of the scientific advisory board of the National Patient Support group for Thyroid Cancer and is heading the National Nuclear Medicine Reference Center of expertise for paediatric thyroid cancer.



Programme

Thursday, November 9th, 2023, from 11 a.m. to 1.30 p.m. (Cairo Local Time)

10.30 a.m. – 11.00 a.m. Registration

Greeting Words

Dr Carsten-Michael Walbiner
Director of the DAAD Regional Office Cairo

11.00 a.m.- 11.15 a.m.

Lorena Mohr
Head of Science and Protocol at the Embassy of the Federal
Republic of Germany in Cairo

11.15 a.m. – 12.00 p.m. Presentation “Theranostics of Nuclear Medicine”
Prof. Dr Markus Luster
Philipps-Universität Marburg

12.00 p.m. – 12.30 p.m. Q & A Session

12.30 p.m. – 1.30 p.m. Joint Networking Lunch

End of Event